We have previously reported on a phase 1 study [5] comprising 37 patients with Castleman disease treated with the anti-IL-6 monoclonal antibody siltuximab, which directly neutralizes IL-6, a key cytokine in the pathogenesis of MCD. The gene discussed is IL6; the disease is Castleman disease.